Taysha Gene Therapies, Inc. Operating Expenses
Taysha Gene Therapies, Inc. (TSHA) reported Operating Expenses of $47.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Taysha Gene Therapies, Inc. operating expenses for the quarter ending 2026-06-30 was $47.35M, a 64.76% increase year-over-year.
- Taysha Gene Therapies, Inc. operating expenses for the quarter ending 2026-03-31 was $43.49M, a 83.31% increase year-over-year.
- Taysha Gene Therapies, Inc. operating expenses for the quarter ending 2025-12-31 was $33.78M, a 53.89% increase year-over-year.
- Taysha Gene Therapies, Inc. operating expenses for the quarter ending 2025-09-30 was $34.02M, a 22.89% increase year-over-year.
- Taysha Gene Therapies, Inc. operating expenses for fiscal 2025 was $120.27M, a 20.52% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. operating expenses for fiscal 2024 was $99.79M, a 13.54% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. operating expenses for fiscal 2023 was $87.89M, a 46.72% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. operating expenses for fiscal 2022 was $164.95M, a 4.80% decline from fiscal 2021.
| Period end | Operating Expenses 0 month | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $47.35M 10-Q · filed 2026-08-11 | $90.83M 10-Q · filed 2026-08-11 | $124.62M derived: sum of 3 quarters · filed 2026-08-11 | $158.64M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $43.49M 10-Q · filed 2026-05-06 | $77.27M derived: sum of 2 quarters · filed 2026-05-06 | $111.30M derived: sum of 3 quarters · filed 2026-05-06 | $140.03M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $33.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $67.81M derived: sum of 2 quarters · filed 2026-03-19 | $96.55M derived: sum of 3 quarters · filed 2026-08-11 | $120.27M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $34.02M 10-Q · filed 2025-11-04 | $62.76M derived: sum of 2 quarters · filed 2026-08-11 | $86.49M 10-Q · filed 2025-11-04 | $108.44M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $28.74M 10-Q · filed 2026-08-11 | $52.46M 10-Q · filed 2026-08-11 | $74.42M derived: sum of 3 quarters · filed 2026-08-11 | $102.10M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $23.72M 10-Q · filed 2026-05-06 | $45.68M derived: sum of 2 quarters · filed 2026-05-06 | $73.36M derived: sum of 3 quarters · filed 2026-05-06 | $95.77M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $21.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $49.64M derived: sum of 2 quarters · filed 2026-03-19 | $72.05M derived: sum of 3 quarters · filed 2026-03-19 | $99.79M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $27.69M 10-Q · filed 2025-11-04 | $50.10M derived: sum of 2 quarters · filed 2025-11-04 | $77.84M 10-Q · filed 2025-11-04 | $97.69M derived: sum of 4 quarters · filed 2025-11-04 | ||||
| 2024-06-30 | $22.41M 10-Q · filed 2025-08-12 | $50.15M 10-Q · filed 2025-08-12 | $70.00M derived: sum of 3 quarters · filed 2025-08-12 | $91.00M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $27.74M 10-Q · filed 2025-05-15 | $47.59M derived: sum of 2 quarters · filed 2025-05-15 | $68.59M derived: sum of 3 quarters · filed 2025-05-15 | $94.37M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $19.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $40.85M derived: sum of 2 quarters · filed 2025-02-26 | $66.63M derived: sum of 3 quarters · filed 2025-02-26 | $87.89M 10-K · filed 2025-02-26 | ||||
| 2023-09-30 | $21.00M 10-Q · filed 2024-11-13 | $46.77M derived: sum of 2 quarters · filed 2024-11-13 | $68.04M 10-Q · filed 2024-11-13 | $124.51M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $25.78M 10-Q · filed 2024-08-12 | $47.04M 10-Q · filed 2024-08-12 | $103.51M derived: sum of 3 quarters · filed 2024-08-12 | $128.97M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $21.27M 10-Q · filed 2024-05-14 | $77.73M derived: sum of 2 quarters · filed 2024-05-14 | $103.19M derived: sum of 3 quarters · filed 2024-05-14 | $136.56M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $56.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $81.92M derived: sum of 2 quarters · filed 2024-03-19 | $115.30M derived: sum of 3 quarters · filed 2024-03-19 | $164.95M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | $25.46M 10-Q · filed 2023-11-14 | $25.07M 10-Q · filed 2022-11-08 | $58.83M derived: sum of 2 quarters · filed 2023-11-14 | $108.48M 10-Q · filed 2023-11-14 | $107.33M 10-Q · filed 2022-11-08 | $158.21M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $33.37M 10-Q · filed 2023-08-14 | $32.98M 10-Q · filed 2022-08-11 | $83.02M 10-Q · filed 2023-08-14 | $82.25M 10-Q · filed 2022-08-11 | $132.75M derived: sum of 3 quarters · filed 2023-08-14 | $183.43M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $49.65M 10-Q · filed 2023-05-11 | $49.27M 10-Q · filed 2022-05-16 | $99.38M derived: sum of 2 quarters · filed 2023-05-11 | $150.06M derived: sum of 3 quarters · filed 2023-05-11 | $190.83M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $49.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $100.41M derived: sum of 2 quarters · filed 2023-03-28 | $141.18M derived: sum of 3 quarters · filed 2023-03-28 | $173.27M 10-K · filed 2023-03-28 | ||||
| 2021-09-30 | $50.68M 10-Q · filed 2022-11-08 | $91.45M derived: sum of 2 quarters · filed 2022-11-08 | $123.54M 10-Q · filed 2022-11-08 | $141.91M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $40.77M 10-Q · filed 2022-08-11 | $72.86M 10-Q · filed 2022-08-11 | $91.23M derived: sum of 3 quarters · filed 2022-08-11 | $106.27M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $32.09M 10-Q · filed 2022-05-16 | $50.46M derived: sum of 2 quarters · filed 2022-05-16 | $65.50M derived: sum of 3 quarters · filed 2022-05-16 | $69.51M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $18.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $33.41M derived: sum of 2 quarters · filed 2022-03-31 | $37.42M derived: sum of 3 quarters · filed 2022-03-31 | $43.00M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $15.04M 10-Q · filed 2021-11-10 | $19.05M derived: sum of 2 quarters · filed 2021-11-10 | $24.64M 10-Q · filed 2021-11-10 | $25.75M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $4.01M 10-Q · filed 2021-08-16 | $9.59M 10-Q · filed 2021-08-16 | $10.71M derived: sum of 3 quarters · filed 2021-08-16 | |||||
| 2020-03-31 | $5.58M 10-Q · filed 2021-05-11 | $6.70M derived: sum of 2 quarters · filed 2021-05-11 | ||||||
| 2019-12-31 | $1.11M 10-K · filed 2021-03-03 | |||||||
| 2019-09-30 | $31.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |